Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Patterson Companies (NasdaqGS:PDCO) ...

Analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Galapagos in a note issued to ...

Fintel reports that on December 11, 2024, Leerink Partners initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a ...

Leerink analyst Mani Foroohar lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $40 from $44 and keeps an Outperform rating ...

Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the ...

Leerink Partners has recently initiated Elanco Animal Health Inc (ELAN) stock to Market Perform rating, as announced on December 2, 2024, according to Finviz. Earlier, on Septembe ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a ...

Leerink analyst David Risinger upgraded AbbVie (ABBV) to Outperform from Market Perform with a $206 price target The firm recommends taking advantage of the emraclidine setback and election ...

Leerink initiated coverage of Janux Therapeutics (JANX) with an Outperform rating and $79 price target Janux’s TRACTr platform solves the therapeutic window problem that has historically plagued ...

The FDA approval represented the first significant innovation in the approach used to treat schizophrenia in decades.

Industry Veterans Grant Curry and Jason Truman Join Leerink Partners. BOSTON, Nov. 14, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, announced today ...